RVDHP is a recently discovered endocannabinoid that acts as a CB1 agonist. RVDHP actually has a higher affinity for CB1 than any other true cannabinoid, this justifies RVDHP being classified as an endocannabinoid. RVDHP suppresses the secretion of adrenalin and noradrenalin from the adrenal cortex and may therefore have therapeutic potential in stress-relief or anxiety disorders or PTSD.